Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Other Operating Expenses: 2009-2019

Historic Other Operating Expenses for Northwest Biotherapeutics (NWBO) over the last 8 years, with Dec 2019 value amounting to -$3.3 million.

  • Northwest Biotherapeutics' Other Operating Expenses fell 826.56% to -$3.3 million in Q4 2019 from the same period last year, while for Sep 2019 it was $3.7 million, marking a year-over-year decrease of 33.48%. This contributed to the annual value of $4.5 million for FY2018, which is 50.18% down from last year.
  • According to the latest figures from Q4 2019, Northwest Biotherapeutics' Other Operating Expenses is -$3.3 million, which was down 505.86% from $802,000 recorded in Q3 2019.
  • In the past 5 years, Northwest Biotherapeutics' Other Operating Expenses registered a high of $6.6 million during Q4 2015, and its lowest value of -$3.3 million during Q4 2019.
  • Moreover, its 3-year median value for Other Operating Expenses was $1.4 million (2017), whereas its average is $1.1 million.
  • In the last 5 years, Northwest Biotherapeutics' Other Operating Expenses spiked by 31,433.33% in 2016 and then slumped by 826.56% in 2019.
  • Quarterly analysis of 5 years shows Northwest Biotherapeutics' Other Operating Expenses stood at $6.6 million in 2015, then slumped by 76.48% to $1.5 million in 2016, then dropped by 2.33% to $1.5 million in 2017, then tumbled by 70.35% to $448,000 in 2018, then slumped by 826.56% to -$3.3 million in 2019.
  • Its last three reported values are -$3.3 million in Q4 2019, $802,000 for Q3 2019, and $914,000 during Q2 2019.